President Donald Trump has increased pressure on Health and Human Services Secretary Robert F. Kennedy Jr. to investigate the potential link between vaccines and autism. This shift comes despite previous advisories from senior administration officials who aimed to steer Kennedy away from the topic ahead of the 2026 midterm elections. During a televised Cabinet meeting at Camp David, Trump inquired about the progress of autism research, to which Kennedy responded that they would have an answer soon. Trump's focus on this issue contrasts with the concerns of White House advisers, who worry that discussing vaccine skepticism could alienate voters.
Recent polling indicated that a majority of Republican voters view vaccines as effective against infectious diseases. However, sources within Trump's circle revealed that he is encouraging Kennedy to explore reducing the number of vaccines administered to children and to examine the alleged connection between vaccines and autism. According to the Centers for Disease Control and Prevention, approximately 1 in 31 children in the U.S. were diagnosed with autism in 2022, a significant increase from 1 in 150 in 2000. While the causes for this rise remain unclear, factors such as genetics and improved screening have been suggested.
In previous comments, Trump expressed skepticism about the hepatitis B vaccine being administered at birth and suggested that the FDA should separate the components of the MMR vaccine. White House spokesman Kush Desai stated that concerns regarding rising autism rates have been overlooked in the past but emphasized that the Trump administration is committed to addressing these issues through scientific research.
The administration has also seen personnel changes, with officials who hold more traditional public health views gaining influence. Some of Trump's nominees with controversial views on vaccines have faced challenges during the Senate confirmation process. As the year progresses, there are concerns that a renewed focus on vaccine policy could complicate the confirmation of other HHS nominees, especially under the current Senate health committee leadership.